Patient, community, and clinician beliefs about multi-cancer detection tests: implications for the evidence needed to recommend routine use
Patients and clinicians want better evidence before routine use of MCD testing for cancer screening. Future research should prioritize rigorous randomized controlled trials that evaluate cancer-mortality, quality of life, diagnostic workup, and potential harms.
Authors
- Bernard F. Fuemmeler (ORCID: https://orcid.org/0000-0002-3550-0107)
- Bryan A. Bassig (ORCID: https://orcid.org/0000-0002-0278-8597)
- Rebecca Davidson Kaltman (ORCID: https://orcid.org/0000-0003-1373-2879)
- Scott M. Strayer (ORCID: https://orcid.org/0000-0002-7879-1311)
- Rebecca Alemu
- Gabriela Villalobos
- Carrie A. Miller (ORCID: https://orcid.org/0000-0002-8136-7618)
- Krist Ah
- Patrick Nana‐Sinkam
- Cynthia Allen
- E Marshall Brooks
- John Sayles
- Jennifer F May
- Kendra Rowe
Institutions
- Sentara Norfolk General Hospital (US)
- Virginia Commonwealth University (US)
- Inova Fairfax Hospital (US)
- Virginia Cancer Institute (US)
- Sentara Heart Hospital (US)
Publication Details
- Journal
- Journal of Public Health
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1093/pubmed/fdag001
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 0.00